English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

As clinicians, we readily appreciate that this study has significant implications for our daily practice. These findings challenge us to revisit a fundamental therapeutic approach against antibioticresistant bacteria and reward us with a needed alternative to carbapenems for the treatment of ESBL-producing E. coli bloodstream infections. Beyond that, this study may herald a renaissance of BLBLI therapy in the era of ‘‘bad bugs, no drugs.’’ For years, the paradigm of how to treat

Can We Really Use ß-Lactam/ß-Lactam Inhibitor Combinations for the Treatment of Infections Caused by Extended-Spectrum ß-Lactamase–Producing Bacteria?